GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker.

GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new company on the London Stock Exchange set for 18 July.

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

View all information regarding the medicines that are manufactured by Glaxosmithkline Consumer Healthcare including its generic drug name, trade name, how to use, the price, and its composition.

Arizona Attorney General Kris Mayes announced Thursday her office was suing a pharmaceutical company for alleged "deceptive" ...

Ms. Mayes is seeking a declaration that the company violated the Arizona Consumer Fraud Act, which prohibits companies from selling a new drug at artificially inflated prices, and maximum statutory ...

GSK Consumer’s (GSK’s) Q2FY19 revenue, Ebitda and PAT growth of 14%, 35% and 43% y-o-y, respectively, surpassed estimates. This was the fourth consecutive quarter of strong volume spurt ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...